Qasr El Eyni Hospital

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Retrieved on: 
月曜日, 3月 11, 2024
Therapy, Breast cancer, SAN, Pharmacology, ARIAD Pharmaceuticals, Biotechnology, Baxalta, Bone marrow, Drug development, Prostate, Acute leukemia, Acting, Stomach, Sanofi, Oxaliplatin, Astellas Pharma, Patient, Oncology, Qasr El Eyni Hospital, Stromal cell, Pancreatic cancer, IND, Head, Colorectal cancer, Cancer, Prostate cancer, Medical imaging

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.
  • “Deyaa’s leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need,” said Thane Wettig, Chief Executive Officer of FibroGen.
  • “We will benefit immensely from Deyaa’s broad and deep experience in oncology drug development, including his experiences in both pancreatic and prostate cancers.”
    “I am excited to join FibroGen and lead the clinical development organization at this important time for our company,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • Prior to joining FibroGen, he was the Chief Medical Officer of Triumvira Immunologics Inc. where he led the transition of two novel cell therapy programs into clinical development.

Triumvira Appoints Oncology Industry Veteran Deyaa Adib, M.D., as Chief Medical Officer

Retrieved on: 
木曜日, 10月 28, 2021
Oncology, Health, Other Health, Other Science, Research, Science, Biotechnology, Qasr El Eyni Hospital, Pancreatic cancer, Head, Breast cancer, Stomach, Biotechnology, Technology, IPO, Immunologic checkpoint, TAC, Tufts University School of Medicine, Baxalta, Oncology, Drug development, Colorectal cancer, Gastrointestinal stromal tumor, Patient, Pharmacology, American Animal Hospital Association, Symphogen, Large-cell lung carcinoma, Ovarian cancer, Acute leukemia, Astellas Pharma, Sanofi, LAG3, Blueprint, KSQ, Oxaliplatin, CEO, Multimedia, TCR, Acute myeloid leukemia, Program, Therapy, Prostate cancer, Purdue Pharma, ARIAD Pharmaceuticals, Pharmaceutical industry, Medical imaging

Dr. Adib will report to President and CEO Dr. Paul Lammers and will succeed Dr. Sabine Chlosta.

Key Points: 
  • Dr. Adib will report to President and CEO Dr. Paul Lammers and will succeed Dr. Sabine Chlosta.
  • View the full release here: https://www.businesswire.com/news/home/20211028005176/en/
    As a seasoned industry leader, Dr. Adib has over 24 years of medical oncology experience in the biotechnology and pharmaceutical industries, including seven successful registrations across solid tumor and hematologic malignancy indications.
  • He previously served as acting chief medical officer at Rain Therapeutics, where he built the oncology portfolio leading to a successful IPO, and vice president of late-stage development at Blueprint Medicines advancing the development of avapritinib approved for gastrointestinal stromal tumor and advanced systemic mastocytosis.
  • Triumvira is headquartered in Austin, Texas with research facilities in Hamilton, Ontario.

Guardian Recovery Network Opens Two New Intensive Outpatient Addiction Treatment Programs in New Jersey

Retrieved on: 
金曜日, 8月 13, 2021
MAT, Time, Taiwan Centers for Disease Control, Center, Intensive outpatient program, IOP, Freedom, History, Prescription, Providence St. Peter Hospital, Maintenance, Learning, Mental health, Program, Water, Qasr El Eyni Hospital, Cognitive behavioral therapy, Breathwork, Motivational interviewing, Yoga, Family therapy, NEW, Buprenorphine/naloxone, Lorelei Fountain, Medicine, Hospital

In response to the state's tragic battle with the epidemic, Guardian Recovery Network has opened two new intensive outpatient addiction treatment centers in New Jersey, one in Hoboken, the other in New Brunswick.

Key Points: 
  • In response to the state's tragic battle with the epidemic, Guardian Recovery Network has opened two new intensive outpatient addiction treatment centers in New Jersey, one in Hoboken, the other in New Brunswick.
  • Guardian Intensive Outpatient (IOP) utilizes a multi-pronged approach, tackling addiction with a wide variety of medical, clinical and holistic evidence-based addiction treatment methods .
  • By treating the mind, body and soul, Guardian addresses the mental, emotional, physical, social and spiritual aspects of addiction.
  • "Quality drug and alcohol treatment programs are perhaps more critical now then they ever have been," said Amanda Hilzer, Executive Director of New Jersey Operations for Guardian Recovery Network.

Hill International to Manage the EGP 5 Billion Landmark Renovation of the Kasr Al-Ainy Hospitals for Cairo University

Retrieved on: 
火曜日, 10月 6, 2020
Mourad Ainy, Qasr El Eyni Hospital, Association football clubs, Football in Morocco, Association football

Hill International will provide project management services during the design, procurement, and execution stages of the project which involves the renovation of all existing Kasr Al-Ainy hospital buildings and facilities and construct any additional facility buildings if required.

Key Points: 
  • Hill International will provide project management services during the design, procurement, and execution stages of the project which involves the renovation of all existing Kasr Al-Ainy hospital buildings and facilities and construct any additional facility buildings if required.
  • Hill Senior Vice President North Africa Waleed Abdel Fattah said of the award, Kasr Al-Ainy is a landmark facility that traces its roots back to 1827.
  • This legacy of healing continues today, and this project will enable the hospitals professionals to better serve their patients through dramatically improved efficiencies and expanded, customized facilities.
  • This will allow Kasr Al-Ainy to serve more patients at a lower cost, while also improving educational and training capabilities for students and staff.